Home › NCT07743151
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
A Randomized, Open Label, Parallel Group Phase 1 Study to Compare Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MK-1406 as Three Injections Compared With Two Injections in Healthy Adult Participants
Who can join
Ages 18 to 64 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) 18.0 to 32.0 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * History of cancer (malignancy)
About the study
The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.
What is being tested
- MK-1406 (drug)
Sponsor: Merck Sharp & Dohme LLC · Participants: 400 · Started: Sep 10, 2026
Contact the study team
- Toll Free Number · Phone: 1-888-577-8839
Official record on ClinicalTrials.gov — NCT07743151
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.